Loading…
Reported covered position: Leg. Counsel, Leg. Asst., Sen. John Warner
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · 3A
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Source: Senate LDA
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Strengthening Medicare Anti-Fraud Measures Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill); trade ajustment assistance (no specific bill); international trade barriers for beta-agonists (no specific bill)
Trans-Pacific Partnership (no specific bill), biologic data exclusivity (no specific bill), trade promotion authority (no specific bill), treatment of intellectual property in India (no specific bill), Playing Fair on Trade and Innovation Act (H.R. 3167), additives in beef cattle (no specific bill), trade adjustment assistance (no specific bill), international trade barriers for beta-agonists (no specific bill)
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill), Medicaid-style rebates in Medicare Part D (no specific bill), Low-income subsidy co-pays in Part D (no specific bill), Independent Payment Advisory Board (S.351, H.R. 351), sustainable growth rate (H.R. 4302), Medicaid (no specific bill)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Non-interference in Medicare Part D (no specific bill), Medicaid-style rebates in Medicare Part D (no specific bill), Low-income subsidy co-pays in Part D (no specific bill), Independent Payment Advisory Board (S.351, H.R. 351), sustainable growth rate (H.R. 4302), Medicaid (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Protecting the Integrity of Medicare Act of 2014
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Protecting the Integrity of Medicare Act of 2014
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Comprehensive tax reform (no specific bill), transfer pricing of intangibles (no specific bill), territorial tax system (no specific bill), deferral of taxation of foreign earned income (no specific bill), tax base erosion (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill)
Patent Transparency and Improvements Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Patent reform (H.R. 3309, S. 1720 )
Patent Transparency and Improvements Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Patent reform (H.R. 3309, S.1720)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill), Medicaid-style rebates in Medicare Part D (no specific bill), Low-income subsidy co-pays in Part D (no specific bill), Independent Payment Advisory Board (S.351, H.R. 351), sustainable growth rate (H.R. 4302), Medicaid (no specific bill)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
National Diabetes Clinical Care Commission Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill)
Safeguarding America's Pharmaceuticals Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Safeguarding America's Pharmaceuticals Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill)
Drug Quality and Security Act (HR 3204)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Protecting Seniors' Access to Medicare Act of 2013
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Supply chain safety (H.R. 1919, S. 959, S. 957)
Supply chain safety (H.R. 1919, S. 959, S. 957)
Pharmaceutical Quality, Security, and Accountability Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Pharmaceutical Quality, Security, and Accountability Act
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 1919, S. 959, S. 957)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Prescription Drug User Fee Act (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill)
Generating Antibiotic Incentives Now Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (no specific bill); pharmaceutical shortages (H.R. 2245, S. 296)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Preserving Access to Life-Saving Medications Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Hepatitis C education (H.R. 3381); Alzheimer's education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Medicare Decisions Accountability Act of 2011
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Food and Drug Administration Reform Act of 2012
Client: MERCK & CO INC · Firm: MERCK & CO, INC.
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · 3A
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2014 · fourth_quarter · 4A
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · 3A
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2014 · fourth_quarter · Q4
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), base erosion (no specific bill), territorial tax system (no specific bill)
Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), sustainable growth rate (general education, no specific bill), Medicare Part B (general education, no specific bill), Preserving the Integrity of Medicare Act (H.R. 5780)
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116), biosimilars (no specific bill), Alzheimer's education (no specific bill)21st Century Cures (no specific bill), general pharmaceutical industry issues and education
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2014 · third_quarter · Q3
Medicare Part D (general education, no specific bill), low-income subsidy co-pay proposals in Medicare Part D (no specific bill), sustainable growth rate (no specific bill)
Comprehensive tax reform (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill), tax base erosion (no specific bill), territorial tax system (no specific bill)
Intellectual property (general education, no specific bill), patent reform (general education, no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · second_quarter · Q2
Non-interference in Medicare Part D (no specific bill), Medicaid-style rebates in Medicare Part D (no specific bill), Low-income subsidy co-pays in Part D (no specific bill), Independent Payment Advisory Board (S.351, H.R. 351), sustainable growth rate (H.R. 4302), Medicaid (no specific bill)
Trans-Pacific Partnership (no specific bill), biologic data exclusivity (no specific bill), trade promotion authority (no specific bill), treatment of intellectual property in India (no specific bill), Playing Fair on Trade and Innovation Act (H.R. 3167), additives in beef cattle (no specific bill), trade adjustment assistance (no specific bill), international trade barriers for beta-agonists (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2014 · first_quarter · Q1
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351); sustainable growth rate (H.R. 4302)
Alzheimer's education (no specific bill); 340B (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074, S. 539); Eliminating Disparities in Diabetes Prevention, Access and Care Act (H.R. 3322); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill); DISARM (H.R. 4187)
MERCK & CO INC via MERCK & CO, INC.
2013 · fourth_quarter · Q4
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Drug Quality and Security Act (HR 3204)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2013 · first_quarter · 1A
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
MERCK & CO INC via MERCK & CO, INC.
2013 · third_quarter · Q3
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill).
Supply chain safety (H.R. 1919, S. 959, S. 957)
MERCK & CO INC via MERCK & CO, INC.
2013 · second_quarter · Q2
Supply chain safety (H.R. 1919, S. 959, S. 957)
Patent settlements (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2013 · first_quarter · Q1
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Alzheimer's education (no specific bill); 340b (no specific bill); hepatitis C education (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2012 · fourth_quarter · Q4
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Hepatitis C education (H.R. 3381); Alzheimer's education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
MERCK & CO INC via MERCK & CO, INC.
2012 · third_quarter · Q3
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (H.R. 3381); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
MERCK & CO INC via MERCK & CO, INC.
2012 · second_quarter · Q2
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651; S. 3187); incentives for antibiotic research and development (H.R. 2182; H.R. 5651; S. 3187); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill).
MERCK & CO INC via MERCK & CO, INC.
2012 · first_quarter · Q1
Supply chain safety (no specific bill); pharmaceutical shortages (H.R. 2245, S. 296)
Comprehensive Tax Reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
MERCK & CO INC via MERCK & CO, INC.
2011 · fourth_quarter · Q4
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Korea Free Trade Agreement (H.R. 3080); TranPacific Partnership
Deficit Reduction (no specific bill)
MERCK & CO INC via MERCK & CO, INC.
2011 · third_quarter · Q3
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, H.R. 2245)
Patent Reform (H.R. 1249)
MERCK & CO INC via MERCK & CO, INC.
2011 · second_quarter · Q2
Deficit reduction (no specific bill); WTO Cotton agreement (H.R. 2112); FDA funding (H.R. 2112); ADAP funding (no specific bill)
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and devlopment (H.R. 2182); hepatitis C education (no specific bill); pharmaceutical shortages (S. 296, HR. 2245)
Patent Reform (H.R. 1249)
MERCK & CO INC via MERCK & CO, INC.
2011 · first_quarter · Q1
Prescription Drug User Fee Act (no specific bill); importation of pharmaceuticals (no specific bill).
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income.
MERCK & CO INC via MERCK & CO, INC.
2010 · first_quarter · 1A
Rx drug importation into the US, other than by drug manufacturer (no specific bill); requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill); promote public/private partnerships for comparative effectiveness assessments (S. 1213); Physician Payments Sunshine Act of 2009 (S. 301); health care reform; increasing coverage of uninsured; coverage of preventative services; including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
MERCK & CO INC via MERCK & CO, INC.
2010 · third_quarter · Q3
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization. Implementation of the Independent Payment Advisory Board provisions of health care reform bill (H.R. 3590). Reauthorization of the Prescription Drug User Fee Act (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2010 · second_quarter · 2A
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2010 · second_quarter · 2A
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2010 · second_quarter · Q2
Change in formula for Average Manufacturers' Price for Medicaid. Efforts to amend the Medicare Modernization Act to impose government price controls on prescription drugs and to ensure appropriate access to vaccines under Medicare (no specific legislation).
Rx drug importation into the U.S., other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Implementation of comparative effectiveness provisions of health care reform bill (H.R. 3590). Awareness and treatment of viral hepatitis (S. Res. 531; H.R. 3974). Expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MERCK & CO INC via MERCK & CO, INC.
2010 · first_quarter · Q1
RX drug importation into the US, other than by drug's manufacturer (no specific bill). Requiring safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Promote public/private partnerships for comparative effectiveness assessment (S. 1213). Physician Payments Sunshine Act of 2009 (S. 301). Health care reform; increasing coverage of uninsured; coverage of preventative services, including immunizations; expansion of the 340B pricing program to include additional covered entities and inpatient prescription drug utilization; maintaining market-based, private sector health care delivery system. (H.R. 3200; S. 1679; S. 1796; H.R. 3590; H.R. 4872)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
MERCK & CO INC via MERCK & CO, INC.
2009 · fourth_quarter · Q4
Oppose efforts to permit RX drug importation into U.S., other than by drug's manufacturer (no specific bill). Support efforts to require safety and cost savings certification by HHS Sec'y in any Rx drug importation legislation (no specific bill). Support efforts to promote public/private partnerships for comparative effectiveness assessment (S.1213). Issues related to Physician Payments Sunshine Act of 2009 (S. 301). Issues related to health care reform; increasing coverage of uninsured; support efforts to gain coverage of preventive services, including immunizations; prevent 340B pricing expansion; maintaining market-based, private sector health care delivery system. (HR 3200; S. 1679; S. 1796; H.R. 3590)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), HIV education (no specific bill), MODDERN Cures Act of 2013 (H.R. 3116),Prescription Drug User Fee Act (general planning), 21st Century Cures (no specific bill), Strengthening Medicare Anti-Fraud Measures Act of 2013 (H.R. 2925), Big data (general education), Alzheimer's education (no specific bill), biosimilars (general education, no specific bill), general pharmaceutical industry issues and education.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Patent reform (H.R. 3309, S.1720)
Comprehensive tax reform (no specific bill), transfer pricing of intangibles (no specific bill), territorial tax system (no specific bill), deferral of taxation of foreign earned income (no specific bill), tax base erosion (no specific bill), orphan drug tax credit (S.1128), R&D tax credit (no specific bill)
Deficit reduction (no specific bill)
Alzheimer's education (no specific bill), 340B (no specific bill), National Diabetes Clinical Care Commission Act (H.R. 1074, S.539), Eliminating Disparities in Diabetes Prevention Act (H.R. 3322), Oncology education (no specific bill), adult vaccine policies (no specific bill), medication adherence, DISARM (H.R. 4187), ACA Implementation (no specific bill), Hepatitis C education (no specific bill), general pharmaceutical industry education, OTC medicines - dextromethorpan and pseudoephedrine (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill); R&D tax credit (no specific bill).
Patent reform (H.R. 3309, S. 1720 )
Deficit reduction (no specific bill); ADAP funding (no specific bill); omnibus appropriations...
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); Playing Fair on Trade and Innovation Act (HR 3167); additives in beef cattle (no specific bill); trade ajustment assistance (no specific bill); international trade barriers for beta-agonists (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Low Income Subsidy Copays in Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Patent reform (H.R. 3309)
Alzheimer's education (no specific bill); 340b (no specific bill); maternal health education (no specific bill); National Diabetes Clinical Care Commission Act (H.R. 1074); Hepatitis C education (no specific bill); adult vaccine policies (no specific bill); medication adherence (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Patent settlements (no specific bill)
Alzheimer's education (no specific bill); 340b (no specific bill); hepatitis C education (no specific bill).
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Supply chain safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Deficit reduction (no specific bill); ADAP funding (no specific bill); Sequestration of FDA user fees (S. 1413, H.R.2775)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); additives in beef cattle (no specific bill); treatment of intellectual property in India
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill); treatment of intellectual property in India (no specific bill); additives in beef cattle (no specific bill); treatment of intellectual property in India
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Access to over-the-counter medications (no specific bill); compounding (no specific bill)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (S. 351, H.R. 351)
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Patent settlements (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); US-EU trade agreement (no specific bill); trade promotion authority (no specific bill)
Deficit reduction (no specific bill); ADAP funding (no specific bill)
Supply chain safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); permanent normal trade relations with Russia (no specific bill); non-tariff trade barriers on U.S. beef (no specific bill)
Supply chain safety (H.R. 5651; S. 3187); pharmaceutical shortages (H.R. 2245; S. 296;H.R. 5651; S. 3187; H.R. 3381)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, H.R. 5, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill); tax base erosion (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Prescription Drug User Fee Act (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to vaccine immunization (no specific bill); 340b (no specific bill)
Trans-Pacific Partnership (no specific bill); biologic data exclusivity (no specific bill); non-tariff trade barriers on U.S. beef
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942; S 1577); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Prescription Drug User Fee Act reauthorization (no specific bill); importation of pharmaceuticals (no specific bill); incentives for antibiotic research and development (H.R. 2182); hepatitis C education (no specific bill); improvements to immunizations (no specific bills); health literacy (no specific bills); adherence (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Deficit Reduction (no specific bill); WTO Cotton Agreement (H.R. 2112)
Korea, Panama and Colombia Free Trade Agreements (no specifc bills); TransPacific Partnership
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of teh R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Korea, Colombia and Panama Free Trade Agreements (no specific bills); data exclusivity in free trade agrements (no specific bills)
Non-interference in Medicare Part D (no specific bill); Medicaid-style rebates in Medicare Part D (no specific bill); Independent Payment Advisory Board (H.R. 452, S. 668)
Comprehensive tax reform (no specific bill); transfer pricing of intangibles (no specific bill); renewal and expansion of the R&D tax credit (H.R. 942); repatriation (no specific bill); territorial tax system (no specific bill); deferral of taxation of foreign earned income (no specific bill).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Supplemental examination (S. 23)
Deficit reduction (no specific bill)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE